Revolution Medicines is trading near $211 with shorts unwinding and options turning sharply more bullish — yet the CEO just sold over $15 million of stock at the highs, creating a pointed divergence that defines the week's setup.
The most striking shift is in options. The put/call ratio collapsed to 0.52 on Tuesday, more than four standard deviations below its 20-day average of 0.76 — the most aggressively call-skewed reading in the past year. That is a dramatic one-day break from a pattern that had been remarkably stable for weeks, with the PCR holding between 0.73 and 0.81 through all of August until now. Options traders are suddenly pricing the stock far more bullishly than they have at any recent point, well below even the prior 52-week low of 0.16. Short interest reinforces the de-risked tone: shorts have covered roughly 20% of their position over the past month, bringing SI down to about 4.9% of the free float from around 7.1% in late July. Borrowing conditions are loose — availability is over 6,600%, meaning the lending pool is essentially unlimited relative to what's been borrowed — and cost to borrow, though up 40% on the week, remains trivially low at 0.63%. There is no squeeze pressure here; this is orderly short covering, not a short-side panic.
The Street is broadly constructive but not uniformly so. Multiple analysts lifted targets earlier this month following what appears to have been a strong Q2 print — Guggenheim and Needham both sit at $240, Evercore and Truist in the $230s, while Bernstein, still at Market Perform, raised its target from $151 to $179 last Thursday, closing some of the discount but remaining the clear outlier. The consensus mean target at $225 sits modestly above current price, a gap that reflects a stock that has already done most of the work the Street expected. The price-to-book has moved up sharply over 30 days — now at 37x — which, for a pre-profitability oncology biotech burning cash, underscores that investors are paying for pipeline optionality rather than current fundamentals. EPS momentum factor scores rank in the 86th-88th percentile, suggesting the company has been a consistent positive surprise; that likely explains why so much short covering has occurred.
The insider activity cuts against the bullish mood in options. CEO Mark Goldsmith sold just over 70,000 shares across multiple tranches on August 21, netting roughly $15.2 million at prices between $208 and $212 — close to where the stock is today. The General Counsel also sold nearly 8,000 shares the same day for around $1.65 million combined. The 90-day insider net across all transactions is a positive 147,000 shares in nominal terms, suggesting prior buying activity, but the timing of these August sales — clustered at the highs just after what the company appears to have characterised as a strong quarter — is worth noting. Significance scores on each trade were low (2-3 out of 10), indicating these were likely pre-planned programme sales rather than discretionary market-timing decisions, but the aggregate size is material.
Correlated peers moved sharply on the week, with BEAM up 17%, CRSP up 15%, and RXRX up 15% — all outperforming RVMD's flat-to-down week. ROIV also slipped about 2%, providing some comfort that the slight underperformance may be sector-idiosyncratic rather than stock-specific.
The next scheduled earnings are November 6. Between now and then, the data point to watch is whether the put/call ratio's sudden call-heavy break persists or reverts — a sustained shift would suggest investors are building speculative long exposure via options ahead of anticipated clinical data, while a quick reversion back toward 0.76 would imply Tuesday's reading was a one-session positioning anomaly rather than a structural sentiment change.
See the live data behind this article on ORTEX.
Open RVMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
